Small ArfGAP1 (stromal membrane-associated protein 1, SMAP1), a GTPase-activating protein specific for ADP-ribosylation factor 6 (Arf6), which is a small GTPase acting on membrane trafficking and actin remodeling, is frequently mutated in various tumors displaying microsatellite instability (MSI), notably in MSI colorectal cancers (CRC). Genotyping of 93 MSI CRCs (40 stage II, 32 stage III and 21 stage IV) allowed us to underscore that SMAP1 mutation frequency was inversely correlated with disease stage (P ¼ 0.01). Analysis of 46 cancer cell lines showed that SMAP1 mutations occurred only in MSI tumors, and consisted exclusively in short insertion or deletion in the coding 10-adenine repeat, generating a premature termination codon located downstream the ArfGAP domain. SMAP1 transcript levels were significant decreased (P ¼ 0.006), and truncated SMAP1 protein could not be detected in cells displaying biallelic SMAP1 mutations, owing to its sensitivity to proteasome degradation. To investigate the role of SMAP1 mutations, we used the SMAP1-null HCT116 cell line and we established three isogenic SMAP1-complemented clones. Cell proliferation was first assessed in vivo using subcutaneous xenografts into immunodeficient mice. Tumors developed in all animals regardless of the cell line injected, but tumor volumes were significantly smaller for both SMAP1-complemented clones compared with HCT116 (Po0.0001, at the time of killing). In vitro, SMAP1 mutations also increased cell clonogenicity (P ¼ 0.02-0.04), cell proliferation (P ¼ 0.008) by shortening the G2/M phase and decreased cell invasiveness (P ¼ 0.03-0.003). In keeping, SMAP1-complemented HCT116 gained several mesenchymal markers (Snail, Slug and vimentin) considered as a hallmark of epithelial-tomesenchymal transition. These observations are reminiscent of some clinical characteristics of MSI CRCs, notably their larger size and lower rate of metastasis. Our observations suggest that SMAP1 loss-of-function mutations in MSI CRC may contribute to the emerging oncogenic pathway involving abnormal Arf6 regulation.
INTRODUCTION
Colorectal cancers (CRCs) displaying microsatellite instability (MSI) represent 15% of all CRCs. MSI results from the inactivation of the mismatch repair system, which is dedicated to post replicative correction of polymerase errors arising during replication.
1,2 MSI tumors accumulate numerous mutations especially in microsatellites, because these simple sequence repeats are hotspots for indel mutations during replication. 3, 4 Coding microsatellites are most often mononucleotide repeats, 5 in which indel mutations cause a frameshift and a premature termination codon. Transcripts containing a premature termination codon are generally degraded by the nonsensemediated mRNA decay (NMD) system, but mRNA decay may be partially efficient, leading to the synthesis of a truncated protein. 6 Among the numerous mutations arising in mismatch repairdeficient tumors, driver mutations are positively selected during MSI-driven oncogenesis, defining the so-called real target genes. 3, 4 According to a statistical model based on regression analysis of mutation frequency in regard to the repeat tract length, 4 genes carrying a coding 10-adenine repeat (A10) may be considered as real target genes, if mutations occur at a frequency exceeding 56% in MSI CRCs.
We have recently identified several novel putative MSI-driven target genes, including small ArfGAP1 (small ADP-ribosylation factor GTPase-activating protein, known as stromal membraneassociated protein 1, SMAP1), which displayed mutations in 73% cases of the 44 primary MSI CRCs studied, 7 a mutation frequency among the highest in MSI CRCs. 4 The SMAP1 gene, located on chromosome 6q13, 8 encodes a 467-amino acid protein composed of an ArfGAP domain, a C4 type zinc finger, a clathrin binding domain and a CALM (clathrin assembly lymphoid myeloid leukemia) protein binding domain. 9 SMAP1 binds directly to the clathrin heavy chain, and regulates clathrin-dependent endocytosis of transferrin receptor 10 and E-cadherin. 11 SMAP1 shows a high degree of homology with SMAP2, a recently identified SMAP gene family member acting as an Arf1-specific ArfGAP in the clathrin-dependent early endosome to trans-Golgi network traffic, 9, 12 which harbors a coding A8 repeat. At the 1 protein level, SMAP1 and SMAP2 share 63% overall similarities, and 90% amino acid identity for the ArfGAP domains. SMAP1 is an ArfGAP that acts on Arf6, 10 a small GTPase involved in various cellular functions, including clathrin-dependent endocytosis, actin remodeling and cytokinesis. 13 Arf6 is involved in cell invasiveness by acting on several molecular processes, notably E-cadherin endocytosis, 14 the first step of epithelial-tomesenchymal transition (EMT). Furthermore, Arf6-GTP has a role in actin remodeling by acting on Rac1, a small GTPase involved in actin polymerization. 14 The amount of Arf6-GTP is correlated to tumor aggressiveness of breast cancer 15 and melanomas 16 , further underlining that Arf6 is a key molecule in tumor progression.
In this study, we report that SMAP1 mutations arise frequently in human MSI tumors of various tissue origins, both in solid tumors and in lymphomas, exclusively targeting the A10 repeat, while no mutation could be detected in the SMAP2 A8 tract. In MSI CRCs, SMAP1 mutation frequency was inversely related to tumor tumornode-metastasis stage, being highest in stage II CRCs that are devoid of local or distant metastasis, suggesting that SMAP1 mutations may counteract tumor metastatic potential. Using various cell lines, we show that MSI-driven SMAP1 frameshift mutations are loss-of-function mutations, as they led to decreased levels of abnormal transcripts, and to subsequent degradation of residual truncated protein by the proteasome. Using a cellular experimental system consisting of the SMAP1-null HCT116 cell line and three isogenic SMAP1-complemented clones, we show that SMAP1 inactivation increased clonogenic capacities and cell proliferation, owing to shorter G2/M phase of the cell cycle, but reduced cell invasiveness by hampering EMT. In keeping, restoring wild-type SMAP1 expression in HCT116 was associated with the expression of several mesenchymal markers (Snail, Slug and vimentin). In vivo, subcutaneous xenografts into immunodeficient mice demonstrated that the tumors were significantly larger upon the injection of HCT116 cells compared with SMAP1-complemented clones. These observations are in agreement with some of the characteristic clinical features of MSI tumors, which are known to be large-sized and poorly invasive tumors. Figure 1a , Table 1 ), indicating that disease extension and SMAP1 mutation frequency are significantly inversely correlated (P ¼ 0.01, w 2 test for trend). By contrast, no mutation could be found in the SMAP2 coding A8 repeat among the 53 primary MSI CRCs analyzed ( Table 1) . As shown by immunohistochemistry, SMAP1 is expressed in the cytoplasm of adjacent normal colonic mucosa (Figure 1b) . Among the tumors displaying SMAP1 mutations, some showed a homogeneous negative pattern, whereas others showed a heterogeneous SMAP1 expression pattern ( Figure 1b) ; the fact that some areas of the tumor displayed normal expression, while others were negative, indicate that SMAP1 mutations did not arise at an early stage of tumor development, but rather appeared during tumor progression in limited tumor areas.
RESULTS

Clinical
Characterization of SMAP1 and SMAP2 mutations in cancer cell lines Indel mutations arising in the SMAP1 A10 and SMAP2 A8 coding repeats were screened in 46 cell lines established from 25 MSI and 21 MSS (microsatellite stable) tumors from various tissues (Figures 2a and b) . Cell lines established from MSI CRCs displayed the highest mutation frequency, with 11 of 14 cell lines having SMAP1 mutations, most often biallelic (8 cell lines) (Figure 2b ). SMAP1 A10 repeat was also frequently mutated in cell lines derived from gastric and endometrial MSI carcinomas, with 3 of 4 cell lines displaying biallelic mutations (Figures 2a and b) . Three of the 7 MSI lymphomas analyzed harbored mutations in SMAP1 A10 repeat, but only monoallelic mutations could be detected (Figures 2a and b ). Deletions were more frequent than insertion, with only 3 cell lines displaying an A11 repeat corresponding to a 1 bp insertion, whereas 25 mutated alleles had lost 1 bp (24 cases) or 2 bp (1 case). None of the cell lines established from the MSS tumors displayed mutations in the SMAP1 A10 repeat (Figure 2a) . No mutation could be found in the SMAP2 A8 coding repeat in any of the 46 cell lines analyzed (Figure 2b ).
To investigate whether SMAP1 mutations were restricted to the A10 repeat or could occur elsewhere, we sequenced the entire coding exons and the exon/intron junctions in cell lines devoid of SMAP1 mRNA levels have been quantified in 13 MSI and 8 MSS cell lines, and expressed as a ratio using HeLa cells as a reference. As shown in Figure 2c , cell lines lacking SMAP1 mutations expressed SMAP1 mRNA at similar levels regardless of the MSI status, with mean levels of 128±15 vs 105±19 (mean±s.e.m.) for MSS and MSI cell lines, respectively (P ¼ 0.50, Mann-Whitney twotailed test). As expected, SMAP1 transcript levels were significantly lower in the MSI cell lines harboring SMAP1 mutations (40±10) compared with MSS and MSI cell lines lacking SMAP1 mutation (P ¼ 0.006 and P ¼ 0.02, respectively, Mann-Whitney one-tailed test); the decrease in SMAP1 transcript levels was more pronounced for MSI cell lines displaying biallelic mutations (31 ± 13; Po0.001 and P ¼ 0.02, compared with MSS and MSI cell lines) than for those with monoallelic mutations (mean 63; P ¼ 0.02 and P ¼ 0.10, compared with MSS and MSI cell lines, Mann-Whitney one-tailed test) (Figure 2d ). However, SMAP1 transcripts levels in LoVo and SW48 were comparable to cell lines devoid of SMAP1 mutations, despite these two cell lines carried biallelic SMAP1 mutations, suggesting that the NMD system was inefficient (Figure 2c ).
SMAP1 mutations are loss-of-function mutations
In order to determine whether residual levels of mutated transcripts were translated into a truncated protein that might act as a dominant negative, we used a polyclonal antibody recognizing amino acid 101-115 of human SMAP1, within the ArfGAP domain and present in SMAP1 wt and SMAP1 mut forms (Figure 2e) . In HeLa cells with SMAP1 wt genotype, SMAP1 migrated at the expected size (55 kDa) (Figure 2f , left lane), whereas no band could be detected at the size expected for the A9 SMAP1 mut (21 kDa) in the HCT116 cells (Figure 2f , right lane). In HeLa cells transfected with an expression vector of the truncated SMAP1-A9 form, an additional band migrating at the expected size for the truncated A9 SMAP1 mut was revealed, confirming that the antibody could recognize both the wild-type and truncated SMAP1 forms (Figure 2f , middle lane). To determine whether truncated SMAP1 was sensitive to proteasome degradation, we transfected HCT116 cells with either pcDNA3.1-SMAP1wt-HA or pcDNA3.1-SMAP1-A9-HA, and treated with the proteasome inhibitor MG132 or vehicle (Figure 2g ). Expression of p53 increased upon MG132 treatment, showing that proteasome was efficiently inhibited (Figure 2g ). MG132 treatment also increased SMAP1-A9-HA expression, but not that of wild-type SMAP1, indicating that truncated SMAP1 was sensitive to proteasome degradation (Figure 2g ). Yet, proteasome inhibition in HCT116 did not allow cells to express endogenous truncated SMAP1 at a detectable level (Figure 2g ). Thus, because no truncated SMAP1 protein could be detected, SMAP1 mutations are loss-of-function mutations.
SMAP1 expression controls in vivo tumor growth in a xenograft tumor model In order to investigate the consequences of SMAP1 inactivation on oncogenesis, we established an experimental model based on the SMAP1-null HCT116 cell line and HCT116-SMAP1-complemented isogenic clones obtained by stably transfecting the pcDNA3.1-SMAP1wt-HA expression vector; three clones that expressed SMAP1 at a level similar to that of HeLa cells (SMAP1 wt ) were selected ( Figure 3a ). Evidence that SMAP1 was functionally active was obtained by showing that the transferrin receptor endocytosis, a well-known SMAP1-dependent activity, was altered in the three HCT116-SMAP1 isogenic clones compared with HCT116 (see Supplementary Figure S1 and data).
In order to investigate the impact of SMAP1 expression on tumor progression, we performed a series of subcutaneous xenograft experiments in nude mice, using HCT116 and two isogenic HCT116-SMAP1 clones (C7 and C12). Tumors developed in all the animals regardless of the cell line injected, indicating that SMAP1 did not influence the frequency of tumor takes. As shown in Figures 3b and c, tumor volumes were significantly smaller for mice implanted with either C7 or C12 SMAP1-positive clone compared with mice injected with parental HCT116 cells, with highly significant P-values (Po0.0001 at the time of killing for both C7 and C12, two-way analysis of variance, ANOVA) ( Figure 3b ). These observations further underline that SMAP1 likely exerts a growth-inhibiting action on xenografted tumors in vivo.
SMAP1 mutations increase clonogenic capacity and cell proliferation by shortening the G2/M phase To better characterize the effects of SMAP1 on cell growth control, we performed in vitro experiments ( Figure 4 ). Restoring SMAP1 expression in HCT116 decreased cell proliferation of all the three HCT116-SMAP1 clones to the same extent; the numbers of cells recovered 48 h after seeding were significantly lower compared By performing a clonogenic assay, we observed that SMAP1 complementation not only decreased the proliferation of HCT116 cells, but also altered their ability to grow when seeded at a low concentration (Figures 4b and c) . The number of clones established from all the three HCT116-SMAP1 clones varied from 28 to 41, which was significantly lower compared with the HCT116 parental cells that gave rise to 70 clones in average (P ¼ 0.02-0.04, t-test). Moreover, the size of colonies derived from HCT116-SMAP1 clones was smaller (Figure 4c ) in agreement with our results showing that restoring SMAP1 expression decreased cell proliferation (Figure 4a) .
Cell cycle analysis of cells synchronized with nocodazole showed that the transition from G2/M to G1 phase was faster for HCT116 cells compared with the HCT116-SMAP1 clones. After 4 h of nocodazole chase, 50% of SMAP1-complemented cells remained in the G2/M phase compared with 20% for HCT116 (P ¼ 0.008) (Figure 4d) , a difference that may explain the proliferation defect observed for the HCT116-SMAP1 clones.
SMAP1 mutations alter adherent junctions, induce mesenchymal markers and decrease cell invasiveness HCT116, in which the expression of SMAP1 was restored, displayed a fibroblast-like phenotype and scattered as compared with HCT116 parental cells that grew in cluster (Figure 5a and data not shown for clone 7 and 16). Immunofluorescence experiments showed that in HCT116, E-cadherin was concentrated at the plasma membrane (Figure 5b, top panel) . In contrast, in HCT116-SMAP1 C12, E-cadherin was mainly located in the cell cytoplasm (Figure 5b, bottom panel) . Similar results were obtained for the two other clones C7 and C16 (data not shown). Accordingly, surface expression of E-cadherin was significantly decreased (ranging from 30 to 70%) in HCT116-SMAP1 clones as attested by flow cytometry analysis using an antibody that recognized the extracellular domain of E-cadherin ( Figure 5c ). As for E-cadherin, immunofluorescence analyses indicated an internalization of b-catenin in HCT116-SMAP1 C12 cell cytoplasm (Figure 5d , bottom panel) in contrast to parental HCT116 cells (Figure 5d , top panel). Furthermore, upon SMAP1 expression, levels of E-cadherin and b-catenin were decreased in the HCT116-SMAP1 clones compared with HCT116 (Figure 5e ).
The gain of mesenchymal markers such as Snail, Slug and vimentin, is a hallmark of EMT. A significant increase of Snail, Slug and vimentin mRNA levels was observed in HCT116-SMAP1 clones as compared with HCT116 (Po0.001, except for vimentin expression in C12, one-way ANOVA, Dunnett's test) (Figure 5f ). The ultimate step of the cells that undergo EMT is to acquire the ability to invade. HCT116-SMAP1 clones were able to invade significantly, more efficiently through a Matrigel layer than the parental HCT116 cell line (Figure 5g ; P ¼ 0.03-0.003, one-way ANOVA, Dunnett's test).
DISCUSSION
In MSI CRCs, only few mutated genes have been clearly demonstrated as having a role in oncogenesis, apart from the transforming growth factor receptor 2 17 and the activin receptor 2 18 that are both involved in the transforming growth factor b pathway. Recently, SMAP1 was found to be among the most frequently mutated genes in MSI CRCs. 7 In this study, we report that loss-of-function SMAP1 mutations occur in MSI tumors of various tissue origins, including CRCs, endometrium and gastric carcinomas, as well as lymphomas. In a series of primary MSI CRCs, immunohistochemical analyses of SMAP1 allowed us to visualize that, in some tumors, SMAP1 protein expression was heterogeneous, with some areas totally lacking detectable SMAP1, while others were normally labeled, indicating that SMAP1 mutations are likely to arise during tumor progression rather than at the initiation step. In our series of CRC patients, SMAP1 mutation frequency was inversely related to the stage of the disease, suggesting that SMAP1 mutations may prevent tumor progression. Thus, it would be interesting to investigate in a larger series of patients with MSI CRC whether the risk for tumor recurrence is lower when tumors homogeneously lack SMAP1 SMAP1 mutations in MSI-driven oncogenic pathway F Sangar et al expression and whether SMAP1 is less frequently mutated in the recurrences. SMAP2, a SMAP1 homolog that codes an ArfGAP specific for Arf1, acting in the retrograde, early endosome-totrans-Golgi network pathway in a clathrin-and AP-1-dependent manner, 12 contains an A8 coding repeat that was devoid of mutations in all the tumors and cell lines analyzed. As the average mutation frequency for A8 repeats is around 10% in MSI CRCs and over 30% to be considered as possibly selected in tumors, our observations suggest that SMAP2 mutations are likely to be neutral in these tumors and may even be counterselected. Alternatively, SMAP1 and SMAP2 mutations may be functionally redundant, as they both target intracellular traffic. On the basis of this SMAP1 mutations in MSI-driven oncogenic pathway F Sangar et al hypothesis, it is not surprising that mutations target predominantly SMAP1 as its repeat is longer, thus being more prone to polymerase slippage during replication.
Several cellular mechanisms exist to avoid the expression of abnormal truncated proteins that may act in a dominant-negative manner. One is the NMD system, which degrades abnormal transcripts harboring a premature termination codon. 6, 19 As expected, SMAP1 mutations caused a significant decrease in SMAP1 transcript levels in cell lines that was more marked for biallelic than for monoallelic mutations, with the exception of LoVo and SW48. The fact that SMAP1 transcript levels remained within the normal range in LoVo and SW48 cells despite the presence of biallelic mutations suggests that NMD may be deficient in these cell lines. Indeed, several genes coding NMD components harbor coding mononucleotide repeats that are prone to MSI-driven mutations, notably SMG7 has one (A)9 repeat and UPF3A has two such repeats. In view of this, it would be interesting to evaluate the contribution of NMD defects in MSI oncogenesis.
In order to get further insights in the molecular mechanisms through which SMAP1 inactivation may drive colorectal oncogenesis, we compared the SMAP1-null HCT116 cell line to three isogenic clones expressing wild-type SMAP1. All HCT116-SMAP1 clones behaved similarly, indicating that the differences observed when compared with the parental HCT116 cell line were most likely due to SMAP1. In vitro cell cultures and in vivo 
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subcutaneous xenograft experiments allowed us to show that the SMAP1-null HCT116 cell line grew significantly faster than its isogenic clones, in which SMAP1 expression was restored. These observations are in line with of one of the characteristic clinical features of MSI CRCs, as they tend to be larger-sized tumors compared with MSS CRCs. Increased cell proliferation associated with SMAP1 mutations was due, as least in part, to a shorter G2/M phase. Interestingly, it was recently reported that the expression of an Arf6 mutant unable to undergo GTP hydrolysis led to cytokinesis defects, suggesting that the hydrolysis of the Arf6-GTP is essential for completion of cytokinesis. 20 It would be interesting to define whether SMAP1 is one of the Arf6GAPs involved in cytokinesis, as its inactivation would increase the Arf6-GTP amount at the plasma membrane, subsequently shortening the G2/M phase, as seen in our experiments. SMAP1 has been previously described as being involved in clathrin-mediated endocytosis of E-cadherin, the main component of the adherent junctions. 11 HeLa cells that normally express SMAP1 internalized E-cadherin efficiently, while those overexpressing wild-type SMAP1 or a GAP-negative mutant failed to internalize E-cadherin, suggesting that Arf6-GTP hydrolysis is necessary for membrane proteins recycling.
11 Clathrindependent E-cadherin endocytosis represents a major pathway controlling the distribution of E-cadherin molecules in adherens junctions of epithelial cells. After its endocytosis, E-cadherin is either recycled back to the membrane or degraded by the proteasome. Why restoring SMAP1 in HCT116 cells significantly decreased the expression of E-cadherin not only at the cell surface, but also its overall expression, without repressing its transcription (data not shown) remains to be elucidated. One possibility could be that SMAP1 regulates the equilibrium between endocytosis, recycling and/or degradation of E-cadherin, a hypothesis that remains to be investigated in CRC cell lines.
Restoring wild-type SMAP1 expression in HCT116 induced several cellular modifications characteristic of EMT: loss of E-cadherin expression at the cell membrane, b-catenin translocation to the nucleus, expression of mesenchymal markers (Snail, Slug and vimentin), cell spreading and increased invasiveness. The fact that SMAP1 inactivation counteracts cell invasion seems not to match the dogma stating that selected mutations are those giving an advantage to the tumor cells. It is important to recall that SMAP1 mutations occur exclusively in mismatch repairdeficient tumors, which continuously accumulate mutations during replication, giving rise to highly heterogeneous populations of cells carrying various combinations of mutations. Some mutations are believed to behave as driver mutations, conferring growth advantage to tumor cells (generally shared by most MSI CRC), while others are considered as passenger mutations, not essential for tumor progression (being present in a minority of MSI CRC cases). Nevertheless, passenger mutations may have a role when arising in combination with additional acquired genetic alterations or in response to specific stimuli, by hampering adequate cellular responses. Thus, we propose that SMAP1 mutations counteract tumor progression only when arising in tumors carrying a particular pattern of alterations that remains to be identified. Using a collection of MSI CRC cell lines displaying various patterns of mutations might give some clues to unravel the signaling pathways involved in response to SMAP1 in the future.
In conclusion, we report that loss-of-function SMAP1 mutations frequently occur in the MSI tumors of various tissue origins, and we provide evidence for their implications in diverse biological functions, unraveling their role in oncogenesis. Owing to the recently reported role for several ArfGAP proteins, including Arf6, in regulating adhesion, migration and cancer cell invasion, 15, 16, 21 we propose to assign a novel role for SMAP1 in this emerging oncogenic pathway.
MATERIALS AND METHODS Patients
This study included 93 patients who underwent surgical resection of histologically proven MSI CRC and for whom clinical data and tumor tissue could be retrieved. The procedures followed in this study were in accordance with the ethical standards of the Institutional Ethics Committee. Tumor type and grade of differentiation were determined according to the World Health Organization criteria. Forty patients had a tumor devoid of lymph node and distant metastasis (stage II), 32 had positive lymph nodes (stage III) and 21 had distant metastasis (stage IV).
Immunohistochemical analyses
Blocks of formalin-fixed paraffin-embedded CRC tissue comprising an area of normal colonic mucosa adjacent to the tumor were selected, as described. 22 Antigen retrieval was performed on 4-mm sections in citrate buffer (pH 6.0) using a microwave technique (15 min at 95 1C), sections were then incubated for 2 h at room temperature with a rabbit antibody against SMAP1 (1/75 dilution, HPA030574, Atlas Antibodies, Stockholm, Sweden) and revealed using the Biogenex Detection kit (Biogenex, Fremont, CA, USA). SMAP1 expression was considered negative when there was a complete absence of staining of neoplastic cells, provided that adjacent lymphocytes, normal epithelial cells, endothelial cells or fibroblasts showed positive staining.
Cell line cultures, proliferation and clonogenic assays
Cell lines were cultured in Dulbecco's Modified Eagle Medium containing stable glutamine (PAA Laboratories GmbH, Velizy, France) supplemented with 10% heat-inactivated fetal calf serum and antibiotics at 37 1C. Cell lines were authenticated using five highly polymorphic (CA)n markers (D2S123, D5S107, D17S1791, D17S250 and D18S1127). For proliferation assays, cells seeded in six-well plates at 12 000 cells per well were harvested 24 or 48 h and counted using the Scepter counter (Millipore, Billerica, MA, USA). For clonogenic assays, cells were seeded at 50 cells per well in 24-well plates, grown for 6 days, then fixed in ice-cold 100% methanol for 10 min at À 20 1C and stained with 1% toluidine blue in 1% borax. Clones were counted using the G:BOX chemiluminescence image analyzer and the GeneTools software (Syngene, Ozyme, Cambridge, UK).
Cell cycle analysis
Cells were seeded in six-well plates at 3 Â 10 5 cells per well, and treated with 50 ng/ml nocodazole during 16 h at day 2. Cells were harvested and counted at various time points; 10 6 cells were fixed in 2 ml ice-cold ethanol 70%, permeabilized with 1% NP40, treated with 1 mg/ml RNase A and labeled with 50 mg/ml propidium iodide. Cells were analyzed by flow cytometry using LSRII cytometer (BD Bioscience, Le Pont de Claix, France). Cell cycle data were calculated using ModFit software (Verity Software House, Topsham, ME, USA).
SMAP1 and SMAP2 genotyping, SMAP1 sequencing
Indel mutations occurring in the SMAP1 A10 and SMAP2 A8 repeats were screened on genomic DNA, as described. 7 The sequencing reactions corresponding to each exon and the flanking sequences of SMAP1 were performed with the Big Dye Terminator v1.1 kit (Applied Biosystems, Grand Island, NY, USA) and one of the primers used for PCR. Primer sequences are available as Supplementary Table S2 . Electrophoreses were run on an ABI PRISM 3100 Genetic Analyzer using 36-cm capillaries and GS Performance Optimized Polymer 7 (Applied Biosystems).
Analysis of SMAP1 transcript expression by quantitative RT-PCR
RNA extraction was performed on cells homogenized with the Mixer Mill MM300 (Qiagen) using the RNeasy Mini kit with a DNA digestion step by DNase I before eluting RNA (Qiagen). Reverse transcription into complementary DNA was performed with the High Capacity cDNA RT kit utilizing random primers (Applied Biosystems). SMAP1 transcript expression was determined with the SMAP1 assay on demand gene expression assay (Hs 00222567) and normalized using 18S (Hs 99999901). Reverse transcription-PCR reactions were performed using an ABI Prism 7900HT (PE Applied Biosystems) and the TaqMan PCR master mix (Applied Biosystems). Amplification plots and predicted threshold cycle (Ct) values were obtained with the Sequence Detector Software (SDS 2.1, Applied Biosystems); ratios between SMAP1 and 18S were calculated as the mean of SMAP1 mutations in MSI-driven oncogenic pathway F Sangar et al the ratios of independent triplicate experiments and expressed relative to the HeLa cell line.
Constructions of the wild-type and mutant SMAP1 HA-tagged expression vectors
The SMAP1 complementary DNA originated from pENTR221-SMAP1 vector (clone IOH27289, Gateway, Life Technologies, Grand Island, NY, USA) was cloned in pcDNA3.1-Hygro þ expression vector (Life Technologies), after site-directed mutagenesis to correct the C1181A mutation (Pro394His). The SMAP1-A9 mutation, corresponding to a 1 bp deletion in the A10 repeat, was obtained by site-directed mutagenesis using the 5 0 -GACAAA AATAAATTGGAGAAAGAAAAGGAAAAAAAAAGGAAGAGAAAAAGAGAGAAA AG-3 0 oligonucleotide and its complementary sequence, as primers. Wildtype SMAP1wt-HA and mutant SMAP1-A9-HA complementary DNAs were cloned in the pcDNA3.1-Hygro þ expression vector, and further genotyped and sequenced, as previously described.
Transfection of HCT116 and HeLa cell lines with wild-type SMAP1wt-HA and mutant SMAP1-A9-HA expression vectors Exponentially growing HeLa cells were transfected with pcDNA3.1-SMAP1-A9-HA and Lipofectamine 2000 (Life Technologies). The HCT116 cell line, which carries a biallelic SMAP1-A9 mutation, was used to establish clones that stably re-expressed a SMAP1 wt allele by transfecting pcDNA3.1-SMAP1wt-HA, using Nucleofector kit (Amaxa, Lonza, Basel, Switzerland). Cells were plated at 300 to 10 000 cells per well in 96-well plates, and selected with 100 mg/ml hygromycin B; resistant clones were screened for the expression of SMAP1wt-HA by western blotting, as described below.
Proteasome inhibition MG132 (Sigma-Aldrich, St Louis, MO, USA) was added to HCT116 cells immediately after transfection with pcDNA3.1-SMAP1wt-HA or pcDNA3.1-SMAP1-A9-HA, incubated for 8 h at 37 1C, and lysed to perform western blot analysis.
Western blot
Total protein extracts (25 mg) obtained by directly lysing cells in Laemmli sample buffer (Bio-Rad, Marnes-la-Coquette, France) were separated on NuPAGE Novex 4-12% Bis-Tris Gels (Life Technologies), transferred onto 0.2 mm nitrocellulose membranes (Bio-Rad), saturated with phosphatebuffered saline containing 0.1% v/v Tween-20 and 5% w/v nonfat dry milk, and analyzed using the following primary antibodies: MaxPab mouse polyclonal antibody anti-SMAP1 (H00060682-B01P, Abnova, Taipei City, Taiwan, 1/1000), mouse monoclonal anti-E-cadherin (HECD-1 clone, Abcam, Cambridge, UK), rabbit whole-serum anti-b-catenin (C2206 clone, Sigma-Aldrich, 1/400), or mouse monoclonal anti-p53 (DO-1 clone, Calbiochem, Darmstadt, Germany, 1/1000) antibodies. Loading controls were performed with a mouse monoclonal anti-GAPDH conjugated with HRP (ab9482, Abcam). Membrane signals were revealed with the SuperSignal West Femto Substrate (Pierce, Rockford, IL, USA), Thermo Fisher Scientific (Illkirch, France), detected and quantified using the G:BOX chemiluminescence image analyzer and the GeneTools software (Syngene).
Mouse xenograft tumor models
Animal experiments were done in accordance with the French Animal Research Committee guidelines. Cells (5 Â 10 6 cells) from HCT116 and two SMAP1-complemented clones (C7 and C12) were implanted subcutaneously into the flank of 5-week-old immunodeficient female mice (NMRI-nu nu/nu; Janvier, Le Genest Saint-Isle, France) (eight mice per group). Measurement of tumor size was performed twice a week using a caliper, and tumor volume (V) was calculated using the formula: V ¼ ab2p/6, where a is the longest and b is the shortest of two perpendicular diameters. After 30 days, animals were killed and tumors were measured and weighted.
Immunofluorescence
Cells grown on cover slips were fixed in paraformaldehyde 2% for 15 min, permeabilized in acetone/methanol (1:1, v/v) 15 min, incubated for 1 h with primary antibodies diluted in phosphate-buffered saline-bovine serum albumin 1% (mouse anti-E-cadherin, HECD-1 clone, at 1/400 or rabbit antib-catenin, C2206, at 1/400), followed by a 1 h incubation with secondary antibodies coupled to Alexa Fluor 488 (Molecular Probes, 1/500); nuclei were stained with 4',6-diamidino-2-phenylindole 300 nM during 10 min. 
Flow cytometry analysis of E-cadherin expression
Invasion assays
Experiments were done in a modified Boyden chamber consisting in an insert with a membrane perforated by 8-mm pores (BD Biosciences) coated with 1 mg/ml Matrigel (BD Biosciences) and placed in 24-wells plates containing complete medium. Cells were incubated on Matrigel in Dulbecco's Modified Eagle Medium for 24 h. Invading cells were fixed in ice-cold methanol 100% during 10 min at À 20 1C and stained with 4',6-diamidino-2-phenylindole 300 nM for 10 min. The membranes were then placed on a cover slip to take pictures that were analyzed with the ImageJ software using the plugging 'Boyden' (INSERM UMR_S 903, Reims, France).
Statistics
Differences in distributions between the variables examined were assessed with the Student's t-test (age distribution), the w 2 (tumor location, stage) or the Fisher's exact test (patients under 65 years, sex, differentiation). Transcript expression levels were compared using a one-tailed MannWhitney test. To analyze SMAP1 mutations frequency according to the tumor-node-metastasis stage of the tumor, we used a w 2 test for trend comparing all data and a two-tailed t-test for pairwise comparisons. For cell proliferation assay, xenograft tumor growth and quantitative reverse transcription-PCR assays, we used a one-way ANOVA, Dunnett's test comparing the clones to the HCT116 parental cell line. For clonogenic and invasion assays, we performed two-tailed t-tests. Analyses were performed using the Prism 5 software (GraphPad Software Inc, La Jolla, CA, USA).
